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Summary Using conventional examination (CE) of H&E stained slides from bone marrow aspirates, meta-
stases can be detected in approximately 25% ofpatients with small cell lung cancer. We investigated a panel of
monoclonal antibodies using immunohistochemistry in the diagnosis of bone marrow infiltration from SCLC
and compared the results with CE. Seven monoclonal antibodies raised against epithelial antigens (CAM 5.2,
MOV 15, NCCST 433, PE 35, LCA1/L38, HMFG 1 AND HMFG2) were applied on bone marrow sections
from three groups of patients (pts): (1) 19 pts in whom SCLC-metastases were detected by CE, (2) 44 pts with
SCLC in whom metastases could not be detected by CE, and (3) 20 pts with non-malignant bone marrow
diseases. All the antibodies except LCA1/L38 were positive in 60-90% of the slides with infiltrating tumour
cells in group 1. No positive tumour cells were detected in group 2. A few plasma cells and megakaryocytes
were slightly positive for MOV 15 and NCCST 433, but no other positive cells were detected in group 3.
In conclusion, the monoclonal antibodies used in this study may be useful for diagnostic purposes when a
suspicious looking infiltration is detected by CE. However, these antibodies could not detect metastatic tumour
cells in the bone marrow sections from patients in whom CE did not reveal any tumour cells.
Bone marrow metastases (BMM) are common in patients
with Small Cell Lung Cancer (SCLC). At the time of the
primary diagnosis, BMM are detected in approximately 25%
of the patients by conventional histologic examination (CE)
(Hirsch et al., 1977; Hirsch & Hansen, 1980), including H&E
stained sections of needle biopsies, aspiration clots and
aspirate smears from the iliac crest. The finding of BMM
may be of prognostic and therapeutic relevance (Hirsch &
Hansen, 1980).
Using various monoclonal antibodies (Mabs) a number of
groups have identified isolated carcinoma cells (presumed
micrometastases) in the bone marrow that were not detected
by CE (Stahel et al., 1985; Hay et al., 1988; Leonard et al.,
1990; Trillet et al., 1989; Cote et al., 1988). In some of the
studies this finding was found to be of prognostic significance
(Leonard et al., 1990). Thus, it appears that routine
cytological and histopathological examination of bone mar-
row may underestimate the rate of BMM in SCLC, which
may be of significance for the clinical management of
patients with SCLC.
In the present study we investigated the usefulness of a
panel of 7 Mabs, included in the panel of antibodies tested at
the International Workshop on Small Cell Lung Cancer
(Souhami et al., 1987), for detecting of BMM in patients
newly diagnosed with SCLC and compared the results with
CE of the bone marrow. For evaluation of the specificity of
the antibodies, a control group of patients with non-
malignant disease who underwent bone marrow examination
was studied.
Materials and methods
Patients
From January 1986 to January 1989 bilateral bone marrow
examinations were performed as part of the pretreatment
staging in a consecutive series of 218 patients (pts) with
SCLC referred to the Finsen Institute. All the patients
received cytostatic treatment according to a prospective ran-
domised trial (Kristjansen et al., 1991). Following the staging
procedure, the 218 pts were classified as having either
regional disease or extensive disease.
Furthermore, in order to examine the reaction of the Mabs
with normal haematopoietic cells, the study included a control
group of 20 pts who underwent bone marrow examination
for non-malignant diseases, e.g. anaemia, thrombocytopenia,
etc.
Histological material
For the present study biopsies from the primary tumours
were obtained by bronchoscopy, mediastinoscopy or
thoracotomy. Bone marrow biopsy and aspiration from the
posterior iliac crest were performed. Only the clot sections
from the aspirate was used. All histological material was
reclassified in accordance with the criteria of the World
Health Organisation (WHO, 1981).
All the tissue, from both primary tumours and clot sec-
tions, were fixed in 10% buffered formalin, dehydrated and
embedded in paraffin, sectioned and stained with H&E for
CE. For immunohistochemistry, five micron sections were
dewaxed and rehydrated, blocked for endogenous peroxidase
activity by ethanol 99%-hydrogenperoxide 1% for 20min,
pretreated with Pronase (Sigma, type 24, No. 8023) for
5 min, and then stained using the antibodies (see Table I).
The primary antibodies were applied for 30 min, and a stan-
dard three step PAP (peroxidase-anti-peroxidase) technique
was used. The peroxidase activity was detected by incubation
in ethylcarbazole for 10min, and a light counterstain was
given by 3 min in Mayers Haematoxylin. As a negative con-
trol the primary antibody was omitted, but otherwise the
same procedure was used.
Evaluation
The immunostaining was assessed by one observer (B.G.S.).
The proportion of stained tumour cells within each section
was estimated and recorded on a scale from 0-4 with zero
representing no positive cells, one indicating 1-10% cells,
two 11-25%, three 26-75%, and four more than 75%
positive tumour cells. Differences in staining intensity were
not evaluated. The primary and secondary tunmours were
evaluated blindly. In all analyses observations with missing
values were excluded. The analysis of age, performance
status, and LDH value was performed by Mann Witney's
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Table I Antibodies used in the study
Antibody Dilution Source Known reaction
CAM 5.2 Undil. Becton- Cytokeratin 8-
supernatant Dickinson 18-19
MOV 15 1:1,000 ICRF Pan epithelial
NCCST 433 1:100 ICRF Carbohydrate
antigen
PE 35 1:100 ICRF Pan epithelial
HMFG 1 Undil. ICRF Epithelial
supematant membrane
antigen
LCA1/L38 1:1,000 ICRF Glycolipid
HMFG 2 Undil. ICRF Epithelial
supernatant membrane
antigen
ICRF = Imperial Cancer Research Fund.
test; the analysis of sex and 'other metastases' by Chi-square
or Fisher's exact test, and the analysis of survival times by
the Kaplan-Meier method and log rank test (Kaplan &
Meier, 1958). Statistical significance was assumed when P
was less than 0.05. Analysis of agreement between CE and
immunohistochemistry was performed by the Kappa method
(Cohen, 1960).
Results
Table II Relation between BMM and other prognostic factors in
patients with SCLC
Results
No. ofpts with No. ofpts with no
Variable BMM (%) BMM (%) P-value
No. of patients 19 44
Age in years 0.19
median 58 62
range (34-68) (47-70)
Sex 0.30
male 12 33
female 7 11
WHO performance 0.17
0-2 7 (52%) 35 (83%)
3-4 6 (48%) 7 (17%)
Extent of disease 0.005
limited 0 18
extensive 19 26
Metastasis in
liver 10 (53%) 9 (20%) 0.02
contralateral lung 2 (13%) 5 (11%) 1.00
CNS 2 (13%) 5 (11%) 1.00
other 1 (5%) 6 (14%) 0.66
S-LDH 0.001
<900U1-' 4 (28%) 32 (84%)
>900U1- 10 (72%) 6 (16%)
Survival (mean days) 202 439 0.001
Three groups of patients were studied. One group included
19 pts in which tissue was available from both primary
biopsies and bone marrow aspiration clots with SCLC metas-
tases diagnosed by CE. In a few ofthese 19 pts the aspiration
clots were very small and only some of the Mabs could be
tested on these specimens. In these cases we chose the Mabs
with the highest known reactivity in the primary tumours.
Another group included 44 pts with SCLC tissue available
for immunohistochemistry from the primary tumour but in
whom CE of the bone marrow did not reveal metastatic
tumour cells.
Finally, the bone marrow aspiration clots from 20 pts
without malignant disease were examined. In each of the
aspiration clots there were at least ten areas of haemopoetic
cells available for diagnosis.
Characteristic ofpts with SCLC
The clinical and pathological characteristics of the patients at
the time of primary diagnosis are shown in Table II. The
significant difference in dissemination of the disease and the
levels of serum LDH in the two groups of pts are in agree-
ment with previous studies (Sagman et al., 1991).
The mean survival time for pts without BMM both by CE
and Mabs was 439 days vs 202 days for pts with BMM
(P<0.001) (Figure 1).
Staining oftheprimary tumours by Mabs
The results of the staining of the primary tumours from pts
with and without BMM by CE are shown in Table III. No
major differences were observed comparing these two groups.
Thus a high proportion of tumour cells were recognised in
the primaries especially for CAM 5.2, MOV 15, PE 35,
NCCST 433 and HMFG 1.
Staining ofthe bone marrow by Mabs
Bone marrow from pts without SCLC In this group a few
plasma cells and megakaryocytes were positive for MOV 15
and NCCST 433 with a cytoplasmic, often intensive reaction
but no other positive cells were detected.
Bone marrow from pts with BMM by CE The results of the
bone marrow examination in pts with metastases by CE are
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Figure 1 Survival curves for patients with SCLC according to
the diagnosis on the bone marrow. ---: Pts without BMM.
: Pts with BMM.
shown in Table IV. The reaction in a few plasma cells and
megakaryocytes was as described above. As for the primary
tumours a high proportion of tumour cells were positive
(> 10% positive cells in each slide) for CAM 5.2 (82%),
MOV 15 (66%), NCCST 433 (42%) and PE 35 (42%). If the
nature of a slightly and/or unevenly stained cell was doubt-
ful, it was scored as non-tumour cell.
Bone marrowfrom pts without BMM by CE As for the bone
marrow from pts without SCLC a few plasma cells and
megakaryocytes were positive for MOV 15 and NCCST 433,
but no other cells were positive, in particular no tumour cells
were detected. All the immunohistochemical controls were
negative. If the nature of a slightly and/or unevenly stained
cell was doubtful, it was scored as non-tumour cell.DETECTING BONE MARROW METASTASES IN SCLC 595
Table III Proportion of staining cells in primary tumours by antibody
Anti- Proportion of staining cells (%)
body NEG 1-10% 11-25% 26-75% > 75% Total
CAM 5.2
+ BMM 1 (5) 0 (0) 1 (5) 4 (21) 13 (69) 19
-BMM 2 (5) 7 (16) 6 (14) 9 (20) 20 (45) 44
MOV 15
+BMM 1 (5) 4 (21) 2 (11) 3 (15) 9 (48) 19
- BMM 4 (9) 1 (2) 6 (14) 8 (18) 25 (57) 44
NCCST-433
+ BMM 3 (15) 4 (22) 3 (15) 4 (21) 5 (57) 19
-BMM 5 (12) 10 (23) 11 (26) 9 (21) 8 (18) 43
PE 35
+BMM 1 (5) 1 (5) 1 (5) 5 (26) 11 (59) 19
- BMM 7 (16) 5 (12) 5 (12) 10 (23) 16 (37) 43
LCA1/L38
+BMM 9 (47) 7 (37) 2 (11) 1 (5) 0 (0) 19
-BMM 29 (71) 8 (20) 1 (2) 2 (5) 1 (2) 41
HMFG 1
+BMM 5 (26) 3 (16) 5 (26) 4 (21) 2 (11) 19
-BMM 11 (41) 3 (11) 4 (15) 7 (26) 2 (7) 27
HMFG 2
+ BMM 5 (26) 4 (21) 6 (32) 3 (16) 1 (5) 19
- BMM 19 (73) 2 (8) 4 (15) 1 (4) 0 (0) 26
Table IV Proportion of staining cells in the bone marrow by antibody
Anti- Proportion of staining cells (%)
body NEG 1-10% 11-25% 26-75% > 75% Total
CAM 5.2
+BMM 1 (6) 2 (12) 0 (0) 7 (41) 7 (41) 17
MOV 15
+ BMM 3 (17) 3 (17) 4 (22) 4 (22) 4 (22) 18
NCCST-433
+ BMM 6 (35) 4 (23) 1 (6) 4 (24) 2 (12) 17
PE 35
+BMM 7 (37) 4 (21) 1 (5) 4 (21) 3 (16) 19
LCA1/L38
+ BMM 14 (82) 1 (6) 1 (6) 1 (6) 0 (0) 17
HMFG 1
+ BMM 4 (33) 4 (33) 3 (25) 1 (9) 0 (0) 12
HMFG 2
+ BMM 4 (33) 5 (42) 1 (8) 2 (17) 0 (0) 12
Comparison between CE and immunohistochemistry
The Kappa value for CE and the two most sensitive Mabs
used in this study (CAM 5.2 and MOV 15) for detection of
BMM were 0.98 and 0.95 respectively.
Discussion
Where metastatic tumour cells are present in bone marrow
from patients with SCLC we have previously reported a high
proportion of positive tumour cells when using the same
panel of antibodies as in the present study (Skov et al., 1991).
However, while the purpose of the first study was to compare
the antigen expression in the bone marrow metastases with
that of the primary tumours, the purpose of the present
study was to compare the diagnostic value of using Mabs
with CE. In the present study we could not detect any
tumour cells by using the panel ofantibodies in bone marrow
without known tumour cells by CE.
The detection of metastases in the bone marrow by means
of Mabs depends on several factors: (1). The antibodies used
and the concentration in which these are applied. (2). Cross
reaction with other bone marrow cells and (3). The method
of investigation.
Re (1): The antibodies applied in the present study have
previously been tested during the SCLC workshops (Souhami
et al., 1987) with evaluation of the optimal concentration and
time of incubation. Furthermore, a large number of tumour
cells were detected both in the primary tumours and in the
bone marrows with metastases diagnosed by CE. Thus, there
are some indications that the described histochemical method
is applicable for SCLC tumour cells. Re (2): With regard to
cross reactivity with normal bone marrow cells, a few plasma
cells and megakaryocytes were positive for MOV 15 and
NCCST 433 in all three groups of pts included in the present
study. Plasma cells and megakaryocytes are rarely confused
with SCLC and such cross reactions are thus of minor
practical significance. Re (3): In most studies on the detection
of micrometastases by Mabs in the bone marrow from
patients with SCLC, immunohistochemistry was used, as de-
scribed below. In a study by Myklebust et al. (1991), both
immunohistochemistry and flow cytometric analysis were
used. Immunocytochemistry proved to be more sensitive than
flow cytometry in the detecting of antibodies binding to both
normal and tumour cells.
Other groups have reported a higher detection rate of bone
marrow metastases by using immunohistochemistry compared
to CE. Hay et al. (1988) applied a panel of 10 Mabs to bone596 B.G. SKOV et al.
marrow aspiration smears from 28 pts with SCLC and from
an unknown number of patients with folate deficiency. Two
of those Mabs, CAM 5.2 and HMFG 2, which were used in
the present study too, did not significantly increase the detec-
tion rate of BMM compared to CE, whereas using a panel of
five other Mabs, including neural associated antibodies
(123A8, UJ 13A), did increase the detection of positive
tumour cells in 75% of the samples. Less than 1% of the
normal marrow cells were positive. In another study from the
same group (Leonard et al., 1990), the same panel of Mabs
was applied on bone marrow smears from 12 pts with no
BMM by CE. In eight of these pts positive tumour cells were
detected. It was stated that any known cross-reactivity with
control marrows was taken into account before SCLC
patients marrows were reported as positive or negative.
Stahel et al. (1985), used a Mab reactive with the surface
membrane of SCLC cells, SM1, and tumour cells were
detected in 69% of bone marrow smears compared to only
16% by CE of bilateral bone marrow examination from 33
patients. Using UJ 13A and an immunofluorescence detec-
tion method on bone marrow aspiration smears, another
group detected positive tumour cells in 4/26 patients with
negative CE. No controls were included (Trillet et al., 1989).
Thus, Mabs - especially those detecting neuroendocrine
antigens - may be of value for detecting micrometastases not
identified by CE. However, unfortunately, most of these
Mabs are not useful on fixed tissue. In all the above men-
tioned studies cytological material was used. Bone marrow
aspiration smears have in some studies been shown to be of
more diagnostic value than bone marrow biopsies in detect-
ing metastases from SCLC by CE (Hirsch et al., 1977).
In the present study no unfixed tissue and no unstained
smears were available for immunohistochemistry. However,
the aim of the present study was to compare the results of
CE of bone marrow aspiration clots to those obtained with
immunohistochemical detection of SCLC cells in the same
aspiration clots, in order to determine if the same (high)
proportion of tumour-positive marrows were detected as by
the cytological examination. Furthermore, compared with
other studies, we have used different Mabs and the technical
procedures were not the same in these studies.
Our results may be contingent on one of two possibilities:
(1) There were infact no metastatic tumour cells in the bone
marrow specimens, and (2) the method used in the present
study were not sensitive enough to detect tumour cells
actually present in the bone marrow specimens. How can the
true diagnosis be established? Assessment of the reliability of
a diagnostic procedure is important. In the present study we
could have used another paraclinical examination, i.e. bone
marrow scanning as a diagnostic tool. Unfortunately, the
results of this examination are often difficult to interpret, the
method is too insensitive to detect minimal metastases
because it depends on the destruction of bone matrix, and
the diagnosis 'BMM' has not been defined with relation to
this procedure. The clinical course of the disease is not useful
as BMM at autopsy may have developed during the time of
observation. Even an in vitro test has been used as a diagnostic
tool. In such a test, the model must imitate all the
physiologic conditions in the human which may influence the
results of what we wish to determine. Thus, it may be
difficult in a meaningful way to determine the accuracy of a
diagnostic method in a representative, random sample of pts.
As suggested by Wulff (1982), perhaps one should forget the
question of the truth of a diagnostic method and only be
interested in the implication of the decision that is made on
the basis of the diagnostic result.
In the present study, pts without detectable tumour cells in
bone marrow by both CE and immunohistochemistry had a
significantly longer survival than pts with BMM. No
differences in these two groups were observed according to
age, sex and performance status (Table II). Hirsch and
Hansen (1980) reported that pts with histologically verified
BMM had a significantly shorter survival than pts with
advanced disease but without bone marrow metastases. If
tumour cells had been overlooked in the marrows in the
present study one would have expected the same (short)
survival in both groups of patients. As immunohistochemi-
stry does not detect tumour cells that are not identified by
CE, the two curves are identical (Figure 1), and this supports
the value of both methods.
Although the Mabs used in this study failed to detect
metastatic tumour cells in bone marrow sections where CE
has not revealed any tumour cells, these Mabs may be useful
for confirmatory diagnostic purposes when a suspicious
infiltration is detected by CE.
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